uniQure files AMT-130 applications on schedule, leaving four-year data as the next test

The filing delivers the milestone investors were already expecting. uniQure had laid out a third-quarter 2026 submission plan, so completing both applications is execution rather than a fresh regulatory surprise. The company announced that it submitted the U.S. BLA and the U.K. MAA. 〔0〕

The regulatory path is open, not secured. The BLA seeks accelerated approval, and uniQure has requested priority review, but neither review acceptance nor approval is established by this filing. 〔1〕 If priority review is granted, the company says the FDA review cycle would be six months after the agency’s 60-day filing review period; that makes this a timing milestone, not an approval event.

The evidence package remains the key vulnerability. The applications rely on the previously announced three-year Phase I/II analysis against a propensity score-matched external control, with no new efficacy magnitude or safety results disclosed here. 〔2〕 The headline claim of slowed disease progression therefore does not materially strengthen the clinical case today.

The next genuine information event is the four-year readout. Management plans to present four-year data before the end of the third quarter. 〔3〕 That update could change how convincing the external-control evidence looks, while the filing itself is best read as a confirmation of the already expected regulatory timetable.